Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA

Acute promyelocytic leukemia (APL) is highly aggressive and is frequently associated with disseminated intravascular coagulation and high early death rates. Although all-trans retinoic acid (RA) induces complete remission in a high proportion of patients with APL, there are limited treatments for APL patients with RA resistance. Here we report an atypical APL patient, with an APL-like disease that developed very slowly without anti-leukemia therapy for nearly 2 years. During that time, the patient only intermittently received anti-HBV drugs, i.e., the combination of adefovir dipivoxil (ADV) and entecavir (ETV), leading us to hypothesize that ADV and/or ETV could inhibit APL progression. Our results showed that anti-HBV drugs ADV and ETV both exhibited significantly inhibitory effects on APL cells, and ADV indicated a much greater cytotoxic effect than ETV on APL cells. We further found that ADV significantly promoted APL cell differentiation and apoptosis, thereby restraining the progression of APL. Most importantly, our study uncovered a novel mechanism of ADV prohibiting APL progression, which was mediated, at least in part, by inhibition of TRIB3 and degradation of the oncoprotein PML-RARA, therefore leading to APL cell differentiation and apoptosis. Taken together, our study demonstrated that ADV, an anti-HBV drug, had significantly inhibitory effects on APL, and provided a novel therapeutic strategy for APL patients with RA resistance.

Automated summary

This study reported a case of atypical APL patient with slow disease progression over nearly 2 years without anti-leukemia therapy. The results showed that anti-HBV drugs ADV and ETV exhibited significant inhibitory effects on APL cells, with ADV demonstrating stronger cytotoxicity. ADV also promoted APL cell differentiation and apoptosis, thereby restraining the progression of APL. The study uncovered a novel mechanism of ADV prohibiting APL progression by inhibiting TRIB3 and degrading PML-RARA.